Multiplikator Forward P/S Wave Life Sciences (WVE)
Diversified routes and laboratory contracts guarantee the continuity of nucleotide supplies for Wave Life Sciences (WVE). Capitalization relies on royalties from pharma behemoths for Huntington's disease and Duchenne muscular dystrophy therapies. An in-house cGMP-standard plant ensures the stable production of RNA drugs. The forward P/S history demonstrates sales valuation dynamics, where the current parameter equals 8.70, which helps in analyzing liquidity risks.
Wave Pharma - rincian analitis lan metrik utama (WVE)
- rega pasar lan target rega analis:
- rincian kapitalisasi pasar:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Utang marang Ekuitas Wave Life Sciences|WVE - Rasio utang jangka dawa marang modal|Utang jangka cendhak marang modal Wave Life Sciences|WVE - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Wave Pharma|WVE - Utang jangka dawa|Utang jangka cendhak perusahaan Wave Life Sciences|Indikator likuiditas cepet wavelifesciences.com
- rincian asil keuangan lan kelipatan valuasi:
WVE - Penghasilan resik|Bathi mangsa ngarep Wave Life Sciences|WVE - Rasio rega marang bathi|Pangali Forward P/E Wave Life Sciences Corp|WVE - Rega marang bathi kanthi panyesuaian wutah|Pangali EV/EBITDA Wave Pharma|WVE - Bathi operasional sadurunge amortisasi|Bathi saben saham sajrone rolas wulan pungkasan Wave Life Sciences|WVE - Bathi saben saham sajrone 12 wulan pungkasan|Wutah bathi EPS kuartalan wavelifesciences.com|WVE - Wutah bathi ing taun lumaku|Prakiraan wutah bathi saben saham kanggo taun ngarep Wave Life Sciences
- indikator volume dodolan lan pendapatan:
Analisis kabeh metrik perusahaan:Wave Life Sciences Ltd. WVE
A defensive portfolio requires strict asset screening through the lens of future value. The forward P/S of Wave Life Sciences (WVE) compares current market capitalization with expected revenue for the following year to identify business overvaluation. For Wave Life Sciences (WVE), this ratio reflects market expectations regarding the monetization of proprietary RNA technologies and stable demand for therapy. The forward P/S dynamics of Wave Life Sciences (WVE) allow for an assessment of the issuer's valuation stability relative to sales growth rates.
Analisis pesaing
Rasio rega marang prakiraan pendapatan Tempus AI, Inc. TEM|Rasio kapitalisasi marang dodolan sing dikarepake Qiagen NV (QGEN)|Ionis Pharma - Multiplikator Forward P/S|Repligen Inc. (RGEN) - Multiplikator forward rega marang pendapatan|RNA: Multiplikator Forward P/S|CRSP - Rasio kapitalisasi marang dodolan sing dikarepake|WGS (GeneDx) - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Ultragenyx Pharmaceutical Inc. RARE|Rasio rega marang prakiraan pendapatan Beam Therapeutics Corp (BEAM)|Sarepta Corp - Kapitalisasi marang prakiraan pendapatan|Multiplikator Forward P/S TWST (Twist Bioscience)|TXG - Multiplikator forward rega marang pendapatan|Intellia Therapeutics, Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Stoke Therapeutics Inc|BioLife Corp (BLFS) - Rasio rega marang prakiraan pendapatan|MAZE - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan SION|Multiplikator forward rega marang pendapatan primemedicine.com (PRME)|Multiplikator forward rega marang pendapatan TSHA (Taysha Gene Therapies, Inc.)|Rasio rega marang prakiraan pendapatan QURE (uniQure NV)|Multiplikator Forward P/S MGTX (MeiraGTx PLC)|REGENXBIO Corp (RGNX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|Solid Biosciences Inc. - Multiplikator Forward P/S|OCGN (ocugen.com) - Kapitalisasi marang prakiraan pendapatan|PacBio (PACB) - Rasio rega marang prakiraan pendapatan|Kapitalisasi marang prakiraan pendapatan BNTC|DSGN (Design Pharma) - Multiplikator Forward P/S|Multiplikator Forward P/S Rocket Corp|Multiplikator forward rega marang pendapatan FDMT (4D Molecular Therapeutics)|Multiplikator forward rega marang pendapatan lexeotx.com LXEO|Multiplikator Forward P/S KRRO (Korro Bio)|Multiplikator Forward P/S Editas Medicine Inc EDIT|SLN: Multiplikator forward rega marang pendapatan|PRQR: Rasio rega marang prakiraan pendapatan|CDXS: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep sangamo.com (SGMO)|Multiplikator forward rega marang pendapatan NAUT|MGX: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Precision BioSciences, Inc. (DTIL)|Rasio rega marang prakiraan pendapatan GBIO (generationbio.com)|Multiplikator Forward P/S BOLD (Boundless Bio, Inc.)|Rasio kapitalisasi marang dodolan sing dikarepake Exicure Inc. (XCUR)|Celsion Corporation - Multiplikator Forward P/S|Rega mangsa ngarep marang pendapatan PHIO|MBIO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep TransCode Therapeutics, Inc. (RNAZ)|Multiplikator forward rega marang pendapatan BNGO|APDN: Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan bluebird bio (BLUE)|Rasio kapitalisasi marang dodolan sing dikarepake immunoprecise.com|Multiplikator Forward P/S OMGA (Omega)|OMIC - Multiplikator forward rega marang pendapatan|Regulus Therapeutics - Multiplikator Forward P/S|Rasio kapitalisasi marang dodolan sing dikarepake syros.com SYRS|TBIO: Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep TRACON Pharmaceuticals Inc. (TCON)|Rasio rega marang prakiraan pendapatan Unity Bio
